- Home
- CTO vs RXST Comparison
CTO vs RXST Comparison
Compare CTO & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- RXST
- Stock Information
- Founded
- CTO 1902
- RXST 1997
- Country
- CTO United States
- RXST United States
- Employees
- CTO N/A
- RXST N/A
- Industry
- CTO Real Estate Investment Trusts
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CTO Real Estate
- RXST Health Care
- Exchange
- CTO Nasdaq
- RXST Nasdaq
- Market Cap
- CTO 589.6M
- RXST 631.1M
- IPO Year
- CTO N/A
- RXST 2021
- Fundamental
- Price
- CTO $18.04
- RXST $13.61
- Analyst Decision
- CTO Strong Buy
- RXST Buy
- Analyst Count
- CTO 3
- RXST 10
- Target Price
- CTO $22.33
- RXST $39.30
- AVG Volume (30 Days)
- CTO 221.2K
- RXST 661.3K
- Earning Date
- CTO 07-24-2025
- RXST 08-04-2025
- Dividend Yield
- CTO 8.43%
- RXST N/A
- EPS Growth
- CTO N/A
- RXST N/A
- EPS
- CTO N/A
- RXST N/A
- Revenue
- CTO $132,203,000.00
- RXST $148,310,000.00
- Revenue This Year
- CTO $20.11
- RXST $22.16
- Revenue Next Year
- CTO $8.51
- RXST $20.91
- P/E Ratio
- CTO N/A
- RXST N/A
- Revenue Growth
- CTO 17.48
- RXST 46.70
- 52 Week Low
- CTO $16.12
- RXST $12.53
- 52 Week High
- CTO $21.15
- RXST $60.81
- Technical
- Relative Strength Index (RSI)
- CTO 44.25
- RXST 38.20
- Support Level
- CTO $17.85
- RXST $13.41
- Resistance Level
- CTO $19.07
- RXST $14.88
- Average True Range (ATR)
- CTO 0.29
- RXST 0.73
- MACD
- CTO -0.06
- RXST -0.14
- Stochastic Oscillator
- CTO 15.16
- RXST 6.78
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.